Observation on the Application Effect of Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer and Analysis of Risk Factors for Recurrence

CUI Guang'e; WEN Shuai; LIU Yingjie; SU Yongqiang; FENG Yanliang; SI Zhigang

doi:10.16458/j.cnki.1007-0893.2025.16.005

Abstract：Objective To analyze the application effect of neoadjuvant chemotherapy in patients with locally advanced breast cancer(LABC)and the risk factors for recurrence.Methods Sixty-two patients with LABC who were diagnosed and received neoadjuvant chemotherapy at the 989th Hospital of the Joint Logistic Support Force of the Chinese People's Liberation Army from August 2021 to August 2024 were selected as the research subjects.They were followed up after treatment to observe the recurrence situation.Univariate and Logistic multivariate analyses were used to analyze the risk factors for recurrence in LABC patients after neoadjuvant chemotherapy.Results Among the 62 patients who received neoadjuvant chemotherapy,24 cases recurred after a follow-up period of 2 to 30 months,with a recurrence rate of 38.71%.Univariate analysis showed that there were statistically significant difference in maximum tumor diameter before treatment,postoperative lymph node stage,human epidermal growth factor receptor 2(HER2),breast cancer metastasis suppressor gene 1(BRMS1),inhibitor of growth factor 4(ING4),cell proliferation nuclear antigen(Ki-67),and estrogen receptor(ER)/progesterone receptor(PR)between the two groups(P<0.05);while there was no statistically significant difference in age,body mass index,family history,pathological type,clinical stage,neoadjuvant chemotherapy regimen,and androgen receptor(AR)status(P>0.05).Logistic multivariate analysis results indicated that maximum tumor diameter>5 cm before treatment,postoperative lymph node stage N3,HER2 status,and high expression of Ki-67 were independent risk factors for recurrence in LABC patients after neoadjuvant chemotherapy(P<0.05).Conclusion After receiving different regimens of neoadjuvant chemotherapy,maximum tumor diameter>5 cm,postoperative lymph node stage N3,HER2 positive,and high expression of Ki-67 are independent risk factors for recurrence in LABC patients.